Amiodarone for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Amiodarone for COVID-19

1 study with 143 patients

Serious outcome risk

Amiodarone

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Amiodarone studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−103%

Mortality (1)−103%

RCTs (1)−103%

Late (1)−103%

00.511.5+

← Amiodarone
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jan 23 2023	Money et al., Cureus, doi:10.7759/cureus.34109	Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study
	Retrospective 420 COVID-19 patients (210 with amiodarone exposure, 210 without) showing no significant difference in pulmonary fibrosis risk with amiodarone use.
Sep 30 2022	Navarese et al., Cardiology Journal, doi:10.5603/CJ.a2022.0072	Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial
	103% higher mortality (p=0.33), 52% higher ventilation (p=0.43), and 30% worse recovery (p=0.19). RCT 215 hospitalized non-intensive care COVID-19 patients showing no significant difference in clinical improvement with amiodarone or verapamil. The trial, which aimed to assess the effects of ion channel inhibitors on COVID-19 progressi..